Biological Activity
Long-acting β2 adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D2, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD).
Compound Libraries
Salmeterol xinafoate is also offered as part of the Tocriscreen Plus and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 603.75 |
| Formula | C25H37NO4.C11H8O3 |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 94749-08-3 |
| PubChem ID | 56801 |
| InChI Key | XTZNCVSCVHTPAI-UHFFFAOYSA-N |
| Smiles | OC(C2=CC(CO)=C(O)C=C2)CNCCCCCCOCCCCC1=CC=CC=C1.OC4=C(C(O)=O)C=CC3=CC=CC=C34 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 60.37 | 100 | |
| ethanol | 12.07 | 20 |
Preparing Stock Solutions
The following data is based on the product molecular weight 603.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.66 mL | 8.28 mL | 16.56 mL |
| 5 mM | 0.33 mL | 1.66 mL | 3.31 mL |
| 10 mM | 0.17 mL | 0.83 mL | 1.66 mL |
| 50 mM | 0.03 mL | 0.17 mL | 0.33 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Akabane et al (2006) Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol.Int. 55 387 PMID: 17130681
Rennard et al (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care Med. 163 1087 PMID: 11316640
Roberts et al (1999) The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur.Respir.J. 14 275 PMID: 10515401
Keywords: Salmeterol xinafoate, supplier, long, acting, beta2, b2, β2, adrenergics, adrenoceptors, agonists, LABAs, asthma, COPD, respiratory, disease, bronchodilators, Adrenergic, Beta-2, Receptors, Adrenergic, Beta-2, Receptors, Tocris Bioscience
